Skip to content
10-Q

Quarterly Report

Sio Gene Therapies Inc.

0001636050-22-000024

← back to feed
Filed
Feb 11, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2022 · Feb 8, 2022 73.71M sh
Current Liabilities Q3 2022 · Dec 31, 2021 $15.14M
Current Liabilities Q3 2022 · Mar 31, 2021 $10.85M
Total Liabilities Q3 2022 · Dec 31, 2021 $17.04M
Total Liabilities Q3 2022 · Mar 31, 2021 $11.78M
Current Assets Q3 2022 · Dec 31, 2021 $90.07M
Current Assets Q3 2022 · Mar 31, 2021 $132.33M
Total Assets Q3 2022 · Dec 31, 2021 $93.31M
Total Assets Q3 2022 · Mar 31, 2021 $135.15M
Net Income Q3 2022 · Mar 31, 2021 −$32.4M
Net Income Q3 2022 · Dec 31, 2020 −$10.52M
Net Income Q3 2022 · Dec 31, 2020 −$29.09M
Net Income Q3 2022 · Sep 30, 2020 −$9.98M
Net Income Q3 2022 · Jun 30, 2020 −$8.59M
Shares Diluted Q3 2022 · Dec 31, 2020 52.68M sh
Shares Diluted Q3 2022 · Dec 31, 2020 47.58M sh
Operating Cash Flow Q3 2022 · Dec 31, 2020 −$36.35M
Cash And Equivalents Q3 2022 · Dec 31, 2020 $81.02M
Cash And Equivalents Q3 2022 · Mar 31, 2020 $80.75M
Stockholders Equity Q3 2022 · Dec 31, 2020 $89.03M
Stockholders Equity Q3 2022 · Sep 30, 2020 $69.67M
Stockholders Equity Q3 2022 · Jun 30, 2020 $58.58M
Stockholders Equity Q3 2022 · Mar 31, 2020 $61.56M
Eps Diluted Q3 2022 · Dec 31, 2020 −$0.20
Eps Diluted Q3 2022 · Dec 31, 2020 −$0.61
Eps Basic Q3 2022 · Dec 31, 2020 −$0.20
Eps Basic Q3 2022 · Dec 31, 2020 −$0.61
Sga Expense Q3 2022 · Dec 31, 2020 $4.2M
Sga Expense Q3 2022 · Dec 31, 2020 $13.33M
Rd Expense Q3 2022 · Dec 31, 2020 $6.41M
Rd Expense Q3 2022 · Dec 31, 2020 $16.66M
Operating Income Q3 2022 · Dec 31, 2020 −$10.7M
Operating Income Q3 2022 · Dec 31, 2020 −$29.4M